No less important, the potential additional influence of germline DNA mutations (BRCA, ATM, MSH, etc.)on prostate cancer prognostication and decision-making cannot be ignored, including patient preference, patient comorbidities, PSA level, histopathological parameters, and imaging findings (especially in the next-generation imaging (NGI) era). This evidence concerns the gene ATM and prostate carcinoma.